Kyle Hoellger
Apr 23, 2015
•
Featured
Coalition for Afforable Drugs Targets Biogen
Kyle Bass' Coalition for Affordable Drugs has filed another IPR, this time directed at Biogen's US 8,759,393, which covers the multiple sclerosis drug Tecfidera. The twice-daily dosage of Tecfidera covered by the '393 patent represents Biogen's top selling drug.